Dengue Vaccine Market is Expected to Garner $ 1.15 Billion by 2024


Posted March 30, 2020 by Steveblade

According to Goldstein Research, global dengue vaccine market is expected to reach USD 1.15 billion by 2024

 
According to Goldstein Research, global dengue vaccine market is expected to reach USD 1.15 billion by 2024 from USD 0.22 billion in 2016, growing at a CAGR of 17.0% over the forecast period through 2024. The major driving factors of the market are increasing dengue fever occurrence, local production of dengue vaccines, promising end stage vaccine pipeline and innovation of live attenuated tetravalent dengue vaccine.
 
Dengue vaccine market segmentation has been carried out on the basis of technology and end user. Government Institutes segment dominated the market and accounted for 45% market share in 2017 and 52% market share by 2024, followed by hospitals, diagnostic labs and NGO’s. Global dengue vaccine market is largely contributed by Brazil and Mexico, estimated to be around USD 0.08 billion in 2016 and grow at a compound annual growth rate (CAGR) of 40%, followed by India, Singapore and Thailand.
 
Market Segmentation
On the basis of our in-depth analysis, Global Dengue Vaccine Market can be segmented as follows:
 
By Technology
Live attenuated vaccine
Chimeric Live attenuated vaccine
Subunit vaccine
Inactivated vaccine
Nucleic acid based vaccine
By End Users
Hospital
Diagnostic Labs
NGO’s
Government Institutes
Others (retail pharmacies, online pharmacies, etc)
 By Region
North America (US, Canada) {Market Share (%), Market Size (USD Billion, Adoption Rate (%)}
Europe (UK, France, Italy, Germany, Spain, Hungary, Sweden, Russia, Poland and Rest of Europe) {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
Middle East and Africa (GCC Countries, North Africa, South Africa and Rest of Middle East & Africa) {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
Latin America (Brazil, Mexico and Rest of Latin America) {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
Asia Pacific (China, Japan, India, Singapore, South Korea, Australia, New Zealand and Rest of Asia-Pacific) {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
Rest of the World {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
 
Request for Sample Report @ https://www.goldsteinresearch.com/request-sample/global-dengue-vaccine-market-outlook-2024-global-opportunity-and-demand-analysis-market-forecast-2016-2024
 
“Global Dengue Vaccine Market Outlook 2024” by Goldstein Research contains detailed overview of the global dengue vaccine market in terms of market segmentation by technology and by end user.
 
Further, Global Dengue Vaccine Market Report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis. This market report also includes competitive outlook of some of the major players profiling of companies such as Sanofi Pasteur, Panacea Biotec, Biological E. Limited, GlaxoSmithKline plc, Merck & Co., Inc., Takeda Pharmaceutical Company Ltd, etc. The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments.
 
Overall, the report represents the global dengue vaccine market trends along with market forecast that will help industry consultants, technology providers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
 
The Report is Available @ https://www.goldsteinresearch.com/report/global-dengue-vaccine-market-outlook-2024-global-opportunity-and-demand-analysis-market-forecast-2016-2024
 
About Goldstein Research
 
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
 
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear cut forecasts. Our market research reports provide in-depth analysis of global and regional variations along with competitors’ overview.
 
Our analysts working on healthcare market research reports to help various tech-giants, tech start-ups and entry players to assess the current and upcoming business scenario. We believe in vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.
 
Contact for more Info:
Steve Blade
(Global Sales Head)
USA: + 1-646-568-7747
Canada:  1-437-886-1181
UK: +44-203-318-6627
[email protected]
www.goldsteinresearch.com
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Goldstein Research
Phone 07520644482
Business Address 99 Wall Street, Suite No 527
Country United States
Categories Health
Tags dengue vaccine market , dengue vaccine market analysis , dengue vaccine market demand , dengue vaccine market forecast 2020 , dengue vaccine market report
Last Updated March 30, 2020